Stay tuned and follow the latest developments and news in Molecular Oncology.
Genekor Medical participated in ESMO Breast 2026 in Berlin, one of the most important international congresses dedicated to breast cancer.
As part of the congress, the scientific team of Genekor Medical participated in the study presented on May 7 in poster format, titled: “Comparison of Methods for Detecting ESR1 Variants in Liquid Biopsy: NGS vs ddPCR”. The study focused on comparing two advanced molecular techniques, Next Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR), for the detection of ESR1 gene mutations in liquid biopsy samples from patients with metastatic breast cancer.
The results, based on 72 samples analyzed with both methods, demonstrated a high concordance rate (94.4%) between NGS and ddPCR in detecting ESR1 mutations, confirming the reliability of both NGS and ddPCR in clinical practice.
At the same time, the research highlighted the complementary advantages of the two technologies: ddPCR offers high sensitivity for targeted monitoring of known mutations, while NGS provides broader genomic coverage and the ability to detect rare mutations, findings that were based on a dataset of more than 2,000 clinical samples.
The participation of Genekor Medical in international scientific congresses reflects the company’s continuous involvement in research and in the development of molecular diagnostics applications for the personalized management of breast cancer.